Gene therapy for Parkinson's disease.

Area of Science:

• Neuroscience
• Molecular Biology
• Regenerative Medicine

Background:

• Parkinson's disease (PD) involves the loss of nigrostriatal dopaminergic neurons, causing motor symptoms like tremor and rigidity.
• Current treatments include L-DOPA medication and deep brain stimulation surgery.
• Cell and gene therapies are emerging as advanced treatment options for PD.

Purpose of the Study:

• To review ex vivo and in vivo gene therapy strategies for Parkinson's disease models.
• To discuss advancements in genetically engineered cell transplantation and viral vector gene transfer.
• To explore future clinical applications and recent gene therapy trials for PD.

Main Methods:

• Ex vivo gene therapy: Transplantation of genetically engineered cells (e.g., catecholamine/neurotrophic factor-secreting cells, with or without encapsulation).
• In vivo gene therapy: Direct injection of viral vectors to enhance dopamine production, promote dopaminergic neuron survival, and correct the brain's microenvironment.
• Review of animal models and recent clinical trials.

Main Results:

• Genetically engineered cell transplantation shows potential for restoring dopaminergic function in PD models.
• In vivo gene therapy using viral vectors can increase dopamine levels and protect existing neurons.
• Gene therapy approaches aim to ameliorate neuronal loss and correct underlying genetic abnormalities in PD.

Conclusions:

• Gene therapy, encompassing both cell-based and direct vector approaches, represents a significant advancement in Parkinson's disease treatment.
• Further research and clinical trials are crucial for translating these promising preclinical findings into effective human therapies.
• The development of advanced molecular biological technologies is accelerating progress in gene therapy for neurodegenerative disorders like PD.